1. Início
  2. Hospital das Clínicas da Faculdade de Medicina - HC
  3. Instituto de Ortopedia e Traumatologia - HC/IOT
  4. Artigos e Materiais de Revistas Científicas - HC/IOT
Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/44208
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorKREYDIN, Evgenyi I.-
dc.contributor.authorGOMES, Cristiano M.-
dc.contributor.authorCRUZ, Francisco-
dc.date.accessioned2021-12-16T14:45:32Z-
dc.date.available2021-12-16T14:45:32Z-
dc.date.issued2021-
dc.identifier.citationINTERNATIONAL BRAZ J UROL, v.47, n.6, p.1091-1107, 2021-
dc.identifier.issn1677-5538-
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/44208-
dc.description.abstractOveractive bladder is a symptom complex consisting of bothersome storage urinary symptoms that is highly prevalent among both sexes and has a significant impact on quality of life. Various antimuscarinic agents and the beta-3 agonists mirabegron and vibegron are currently available for the treatment of OAB. Each drug has specific pharmacologic properties, dosing schedule and tolerability profile, making it essential to individualize the medical treatment for the patient's characteristics and expectations. In this manuscript, we review the most important factors involved in the contemporary pharmacological treatment of OAB.eng
dc.language.isoeng-
dc.publisherBRAZILIAN SOC UROLeng
dc.relation.ispartofInternational Braz J Urol-
dc.rightsopenAccesseng
dc.subjectUrinary Bladdereng
dc.subjectOveractiveeng
dc.subjectDrug Therapyeng
dc.subjectMuscarinic Antagonistseng
dc.subjectUrinary Incontinenceeng
dc.subject.otherurinary-tract symptomseng
dc.subject.otherquality-of-lifeeng
dc.subject.otherbeta(3)-adrenoceptor agonist mirabegroneng
dc.subject.othermuscarinic receptor antagonistseng
dc.subject.otheranticholinergic medication useeng
dc.subject.otherlong-term safetyeng
dc.subject.othertransdermal oxybutynineng
dc.subject.otherintravesical oxybutynineng
dc.subject.othertrospium chlorideeng
dc.subject.otheractive metaboliteeng
dc.titleCurrent pharmacotherapy of overactive bladdereng
dc.typearticleeng
dc.rights.holderCopyright BRAZILIAN SOC UROLeng
dc.identifier.doi10.1590/S1677-5538.IBJU.2021.99.12-
dc.identifier.pmid34003613-
dc.subject.wosUrology & Nephrologyeng
dc.type.categoryrevieweng
dc.type.versionpublishedVersioneng
hcfmusp.author.externalKREYDIN, Evgenyi I.:Univ Southern Calif, Keck Sch Med, Dept Urol, Los Angeles, CA 90007 USA-
hcfmusp.author.externalCRUZ, Francisco:Hosp Sao Joao, Fac Med Porto, Dept Urol, Porto, Portugal; I3S Inst Invest & Inovacao Saude, Porto, Portugal-
hcfmusp.description.beginpage1091-
hcfmusp.description.endpage1107-
hcfmusp.description.issue6-
hcfmusp.description.volume47-
hcfmusp.origemWOS-
hcfmusp.origem.idWOS:000711926100002-
hcfmusp.origem.id2-s2.0-85115441922-
hcfmusp.origem.idSCIELO:S1677-55382021000601091-
hcfmusp.publisher.cityRIO DE JANEIROeng
hcfmusp.publisher.countryBRAZILeng
hcfmusp.relation.referenceAbrams P, 2000, AM J MANAG CARE, V6, pS580eng
hcfmusp.relation.referenceAbrams P, 2007, BJU INT, V100, P987, DOI 10.1111/j.1464-410X.2007.07205.xeng
hcfmusp.relation.referenceANDERSON GF, 1977, PHARMACOLOGY, V15, P31, DOI 10.1159/000136660eng
hcfmusp.relation.referenceAndersson Karl-Erik, 2019, Med Sci (Basel), V7, DOI 10.3390/medsci7050067eng
hcfmusp.relation.referenceAndersson Karl-Erik, 2008, Curr Urol Rep, V9, P459, DOI 10.1007/s11934-008-0079-zeng
hcfmusp.relation.referenceAndersson KE, 2001, WORLD J UROL, V19, P319, DOI 10.1007/PL00007103eng
hcfmusp.relation.referenceAndersson KE, 2017, INCONTINENCE 6 INT C, P805eng
hcfmusp.relation.referenceAppell RA, 2001, MAYO CLIN PROC, V76, P358eng
hcfmusp.relation.referenceAttoh-Mensah E, 2020, DRUG AGING, V37, P301, DOI 10.1007/s40266-019-00743-zeng
hcfmusp.relation.referenceBakali E, 2016, INT UROGYNECOL J, V27, P1393, DOI 10.1007/s00192-016-2984-xeng
hcfmusp.relation.referenceBirder LA, 2012, NEUROUROL URODYNAM, V31, P293, DOI 10.1002/nau.22195eng
hcfmusp.relation.referenceGormley EA, 2015, J UROLOGY, V193, P1572, DOI 10.1016/j.juro.2015.01.087eng
hcfmusp.relation.referenceGratzke C, 2018, EUR UROL, V74, P501, DOI 10.1016/j.eururo.2018.05.005eng
hcfmusp.relation.referenceGray SL, 2015, JAMA INTERN MED, V175, P401, DOI 10.1001/jamainternmed.2014.7663eng
hcfmusp.relation.referenceGriebling TL, 2020, BMC GERIATR, V20, DOI 10.1186/s12877-020-1474-7eng
hcfmusp.relation.referenceHARUNO A, 1992, ARZNEIMITTEL-FORSCH, V42-1, P815eng
hcfmusp.relation.referenceHerschorn S, 2013, UROLOGY, V82, P313, DOI 10.1016/j.urology.2013.02.077eng
hcfmusp.relation.referenceHomma Y, 2008, INT J UROL, V15, P986, DOI 10.1111/j.1442-2042.2008.02152.xeng
hcfmusp.relation.referenceIkeda K, 2002, N-S ARCH PHARMACOL, V366, P97, DOI 10.1007/s00210-002-0554-xeng
hcfmusp.relation.referenceIrwin DE, 2008, EUR UROL, V53, P1029, DOI 10.1016/j.eururo.2008.01.027eng
hcfmusp.relation.referenceIrwin DE, 2011, BJU INT, V108, P1132, DOI 10.1111/j.1464-410X.2010.09993.xeng
hcfmusp.relation.referenceLose G, 2001, BJU INT, V87, P767, DOI 10.1046/j.1464-410x.2001.02227.xeng
hcfmusp.relation.referenceIshikawa K, 2021, UROLOGY, V153, P256, DOI 10.1016/j.urology.2021.01.021eng
hcfmusp.relation.referenceJaggar SI, 1998, PAIN, V76, P189, DOI 10.1016/S0304-3959(98)00041-4eng
hcfmusp.relation.referenceJu RJ, 2014, INT UROGYNECOL J, V25, P479, DOI 10.1007/s00192-013-2246-0eng
hcfmusp.relation.referenceKanayama N, 2007, XENOBIOTICA, V37, P139, DOI 10.1080/00498250601140072eng
hcfmusp.relation.referenceKeam SJ, 2018, DRUGS, V78, P1835, DOI 10.1007/s40265-018-1006-3eng
hcfmusp.relation.referenceKelleher C, 2018, EUR UROL, V74, P324, DOI 10.1016/j.eururo.2018.03.020eng
hcfmusp.relation.referenceKessler TM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016718eng
hcfmusp.relation.referenceKhullar V, 2006, UROLOGY, V68, P38, DOI 10.1016/j.urology.2006.05.043eng
hcfmusp.relation.referenceKhullar V, 2013, BMC UROL, V13, DOI 10.1186/1471-2490-13-45eng
hcfmusp.relation.referenceKhullar V, 2013, EUR UROL, V63, P283, DOI 10.1016/j.eururo.2012.10.016eng
hcfmusp.relation.referenceLozano-Ortega G, 2020, ADV THER, V37, P2344, DOI 10.1007/s12325-020-01318-weng
hcfmusp.relation.referenceKim Y, 2006, BJU INT, V97, P400, DOI 10.1111/j.1464-410X.2005.05913.xeng
hcfmusp.relation.referenceKobayashi F, 2007, ARZNEIMITTELFORSCH, V57, P92eng
hcfmusp.relation.referenceLazarus J, 2009, NAT REV UROL, V6, P671, DOI 10.1038/nrurol.2009.214eng
hcfmusp.relation.referenceLiberman JN, 2001, UROLOGY, V57, P1044, DOI 10.1016/S0090-4295(01)00986-4eng
hcfmusp.relation.referenceLightner DJ, 2019, J UROLOGY, V202, P558, DOI 10.1097/JU.0000000000000309eng
hcfmusp.relation.referenceLipton RB, 2005, J UROLOGY, V173, P493, DOI 10.1097/01.ju.0000148963.21096.5deng
hcfmusp.relation.referenceMacdiarmid Scott A, 2008, Rev Urol, V10, P92eng
hcfmusp.relation.referenceMadhuvrata P, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005429.pub2eng
hcfmusp.relation.referenceMalhotra B, 2009, CURR MED CHEM, V16, P4481, DOI 10.2174/092986709789712835eng
hcfmusp.relation.referenceManiscalco GT, 2018, NEUROL SCI, V39, P97, DOI 10.1007/s10072-017-3148-6eng
hcfmusp.relation.referenceMerrill L, 2016, NAT REV UROL, V13, P193, DOI 10.1038/nrurol.2016.13eng
hcfmusp.relation.referenceMoldwin R, 2015, NEUROUROL URODYNAM, V34, pS50eng
hcfmusp.relation.referenceMorales-Olivas Francisco J., 2010, Archivos Espanoles de Urologia, V63, P43eng
hcfmusp.relation.referenceMukerji G, 2010, UROLOGY, V75, DOI 10.1016/j.urology.2009.12.051eng
hcfmusp.relation.referenceSellers Donna J, 2012, Handb Exp Pharmacol, P375, DOI 10.1007/978-3-642-23274-9_16eng
hcfmusp.relation.referenceNambiar AK, 2018, EUR UROL, V73, P596, DOI 10.1016/j.eururo.2017.12.031eng
hcfmusp.relation.referenceNazir J, 2018, NEUROUROL URODYNAM, V37, P986, DOI 10.1002/nau.23413eng
hcfmusp.relation.referenceNey P, 2008, BJU INT, V101, P1036, DOI 10.1111/j.1464-410X.2007.07358.xeng
hcfmusp.relation.referenceNilvebrant L, 2002, PHARMACOL TOXICOL, V90, P260, DOI 10.1034/j.1600-0773.2002.900506.xeng
hcfmusp.relation.referenceNitti VW, 2014, INT J CLIN PRACT, V68, P972, DOI 10.1111/ijcp.12433eng
hcfmusp.relation.referenceNitti VW, 2013, J UROLOGY, V190, P1320, DOI 10.1016/j.juro.2013.05.062eng
hcfmusp.relation.referenceNitti VW, 2006, UROLOGY, V67, P657, DOI 10.1016/j.urology.2005.11.039eng
hcfmusp.relation.referenceNovara G, 2008, EUR UROL, V54, P740, DOI 10.1016/j.eururo.2008.06.080eng
hcfmusp.relation.referenceOelke M, 2015, AGE AGEING, V44, P745, DOI 10.1093/ageing/afv077eng
hcfmusp.relation.referenceOki T, 2006, EUR J PHARMACOL, V529, P157, DOI 10.1016/j.ejphar.2005.11.004eng
hcfmusp.relation.referenceShin DG, 2019, NEUROUROL URODYNAM, V38, P295, DOI 10.1002/nau.23852eng
hcfmusp.relation.referencePainter KA, 1996, J UROLOGY, V156, P1459, DOI 10.1016/S0022-5347(01)65629-5eng
hcfmusp.relation.referenceReeves P, 2006, EUR UROL, V50, P1050, DOI 10.1016/j.eururo.2006.04.018eng
hcfmusp.relation.referenceRichardson K, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/bmj.k1315eng
hcfmusp.relation.referenceRisacher SL, 2016, JAMA NEUROL, V73, P721, DOI 10.1001/jamaneurol.2016.0580eng
hcfmusp.relation.referenceRovner E, 2020, NEUROUROL URODYNAM, V39, P744, DOI 10.1002/nau.24272eng
hcfmusp.relation.referenceRovner ES, 2004, DRUGS, V64, P2433, DOI 10.2165/00003495-200464210-00005eng
hcfmusp.relation.referenceSmith AL, 2019, COMTEMPORARY PHARMAC, P85eng
hcfmusp.relation.referenceSoler R, 2018, NEUROUROL URODYNAM, V37, P1356, DOI 10.1002/nau.23446eng
hcfmusp.relation.referenceSoler R, 2013, EUR UROL, V64, P610, DOI 10.1016/j.eururo.2013.04.042eng
hcfmusp.relation.referenceStaskin D, 2010, INT J CLIN PRACT, V64, P1294, DOI 10.1111/j.1742-1241.2010.02433.xeng
hcfmusp.relation.referenceStaskin D, 2020, J UROLOGY, V204, P316, DOI 10.1097/JU.0000000000000807eng
hcfmusp.relation.referenceStaskin D, 2010, J AM GERIATR SOC, V58, P1618, DOI 10.1111/j.1532-5415.2010.02988.xeng
hcfmusp.relation.referenceStaskin DR, 2009, J UROLOGY, V181, P1764, DOI 10.1016/j.juro.2008.11.125eng
hcfmusp.relation.referenceTodorova A, 2001, J CLIN PHARMACOL, V41, P636, DOI 10.1177/00912700122010528eng
hcfmusp.relation.referenceBirder L, 2013, PHYSIOL REV, V93, P653, DOI 10.1152/physrev.00030.2012eng
hcfmusp.relation.referenceVan Kerrebroeck P, 2001, UROLOGY, V57, P414, DOI 10.1016/S0090-4295(00)01113-4eng
hcfmusp.relation.referenceWagg A, 2020, EUR UROL, V77, P211, DOI 10.1016/j.eururo.2019.10.002eng
hcfmusp.relation.referenceWagg A, 2015, CUAJ-CAN UROL ASSOC, V9, P343, DOI 10.5489/cuaj.3098eng
hcfmusp.relation.referenceWalczak JS, 2009, NEUROSCIENCE, V159, P1154, DOI 10.1016/j.neuroscience.2009.01.050eng
hcfmusp.relation.referenceWaldeck K, 1997, J UROLOGY, V157, P1093, DOI 10.1016/S0022-5347(01)65148-6eng
hcfmusp.relation.referenceWallace S. A., 2004, COCHRANE DB SYST REV, V1, DOI 10.1002/14651858.CD001308.pub2eng
hcfmusp.relation.referenceWelk B, 2020, BJU INT, V126, P183, DOI 10.1111/bju.15040eng
hcfmusp.relation.referenceWitte LPW, 2009, CURR OPIN UROL, V19, P13, DOI 10.1097/MOU.0b013e32831a6ff3eng
hcfmusp.relation.referenceWuest M, 2011, WORLD J UROL, V29, P149, DOI 10.1007/s00345-011-0655-6eng
hcfmusp.relation.referenceYamada S, 2018, PHARMACOL THERAPEUT, V189, P130, DOI 10.1016/j.pharmthera.2018.04.010eng
hcfmusp.relation.referenceBroderick Jason M., 2020, UROLOGY TIMESeng
hcfmusp.relation.referenceYamaguchi O, 2019, INT J UROL, V26, P342, DOI 10.1111/iju.13868eng
hcfmusp.relation.referenceYamaguchi O, 2013, INT J UROL, V20, P28, DOI 10.1111/iju.12008eng
hcfmusp.relation.referenceYamanishi T, 2020, NEUROUROL URODYNAM, V39, P804, DOI 10.1002/nau.24285eng
hcfmusp.relation.referenceYoshida M, 2019, INT J UROL, V26, P369, DOI 10.1111/iju.13877eng
hcfmusp.relation.referenceYoshida M, 2018, EUR UROL, V73, P783, DOI 10.1016/j.eururo.2017.12.022eng
hcfmusp.relation.referenceZinner N, 2007, EXPERT OPIN PHARMACO, V8, P511, DOI 10.1517/14656566.8.4.511eng
hcfmusp.relation.referenceBrown W, 2017, J PAIN, V18, P726, DOI 10.1016/j.jpain.2017.01.009eng
hcfmusp.relation.referenceBrynne N, 1997, INT J CLIN PHARM TH, V35, P287eng
hcfmusp.relation.referenceBubser Michael, 2012, Handb Exp Pharmacol, P121, DOI 10.1007/978-3-642-23274-9_7eng
hcfmusp.relation.referenceBurkhard FC, 2020, EAU ANN C AMST 2020eng
hcfmusp.relation.referenceBuser N, 2012, EUR UROL, V62, P1040, DOI 10.1016/j.eururo.2012.08.060eng
hcfmusp.relation.referenceBuyse G, 1998, J UROLOGY, V160, P892, DOI 10.1016/S0022-5347(01)62828-3eng
hcfmusp.relation.referenceChancellor MB, 2012, DRUG AGING, V29, P259, DOI 10.2165/11597530-000000000-00000eng
hcfmusp.relation.referenceChapple CR, 2008, EUR UROL, V54, P543, DOI 10.1016/j.eururo.2008.06.047eng
hcfmusp.relation.referenceChapple CR, 2020, EUR UROL, V77, P119, DOI 10.1016/j.eururo.2019.09.024eng
hcfmusp.relation.referenceChapple CR, 2017, EUR UROL, V72, P389, DOI 10.1016/j.eururo.2017.01.037eng
hcfmusp.relation.referenceChoo MS, 2007, WORLD J UROL, V25, P505, DOI 10.1007/s00345-007-0183-6eng
hcfmusp.relation.referenceCockayne DA, 2000, NATURE, V407, P1011, DOI 10.1038/35039519eng
hcfmusp.relation.referenceCoelho A, 2017, NEUROUROL URODYNAM, V36, P1972, DOI 10.1002/nau.23224eng
hcfmusp.relation.referenceCohn JA, 2016, THER ADV UROL, V8, P83, DOI 10.1177/1756287215626312eng
hcfmusp.relation.referenceCorcos Jacques, 2004, Can J Urol, V11, P2278eng
hcfmusp.relation.referenceCorcos J, 2017, CUAJ-CAN UROL ASSOC, V11, pE142, DOI 10.5489/cuaj.4586eng
hcfmusp.relation.referenceCoyne KS, 2011, UROLOGY, V77, P1081, DOI 10.1016/j.urology.2010.08.039eng
hcfmusp.relation.referenceDavila GW, 2006, UROL CLIN N AM, V33, P455, DOI 10.1016/j.ucl.2006.06.005eng
hcfmusp.relation.referenceDavila GW, 2001, J UROLOGY, V166, P140, DOI 10.1016/S0022-5347(05)66095-8eng
hcfmusp.relation.referenceDmochowski Roger R., 2006, Int. braz j urol., V32, P513, DOI 10.1590/S1677-55382006000500003eng
hcfmusp.relation.referenceDmochowski RR, 2003, UROLOGY, V62, P237, DOI 10.1016/S0090-4295(03)00356-Xeng
hcfmusp.relation.referenceDmochowski RR, 2005, WORLD J UROL, V23, P263, DOI 10.1007/s00345-005-0012-8eng
hcfmusp.relation.referenceDmochowski RR, 2002, J UROLOGY, V168, P580, DOI 10.1016/S0022-5347(05)64684-8eng
hcfmusp.relation.referenceDrake MJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170726eng
hcfmusp.relation.referenceDrake MJ, 2016, EUR UROL, V70, P136, DOI 10.1016/j.eururo.2016.02.030eng
hcfmusp.relation.referenceDumoulin C, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005654.pub2eng
hcfmusp.relation.referenceFarquhar-Smith WP, 2002, PAIN, V97, P11, DOI 10.1016/S0304-3959(01)00419-5eng
hcfmusp.relation.referenceFick DM, 2019, J AM GERIATR SOC, V67, P674, DOI 10.1111/jgs.15767eng
hcfmusp.relation.referenceFreeman R, 2018, CURR MED RES OPIN, V34, P785, DOI 10.1080/03007995.2017.1419170eng
hcfmusp.relation.referenceFry CH, 2020, NEUROUROL URODYNAM, V39, pS113, DOI 10.1002/nau.24228eng
hcfmusp.relation.referenceGiglio D, 2009, PHARMACOLOGY, V83, P259, DOI 10.1159/000209255eng
hcfmusp.relation.referenceGoldman HB, 2014, CURR MED RES OPIN, V30, P509, DOI 10.1185/03007995.2013.860021eng
hcfmusp.relation.referenceGomelsky A, 2019, NEUROUROL URODYNAM, V38, P825, DOI 10.1002/nau.23895eng
hcfmusp.relation.referenceGomes CM, 2020, CURR MED RES OPIN, V36, P1403, DOI 10.1080/03007995.2020.1760806eng
hcfmusp.relation.referenceGonzalez-Sanchez B, 2016, WORLD J UROL, V34, P979, DOI 10.1007/s00345-015-1703-4eng
dc.description.indexMEDLINEeng
dc.identifier.eissn1677-6119-
hcfmusp.citation.scopus13-
hcfmusp.scopus.lastupdate2024-03-29-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - HC/IOT
Instituto de Ortopedia e Traumatologia - HC/IOT

Artigos e Materiais de Revistas Científicas - LIM/55
LIM/55 - Laboratório de Urologia


Files in This Item:
File Description SizeFormat 
art_KREYDIN_Current_pharmacotherapy_of_overactive_bladder_2021.PDFpublishedVersion (English)280.52 kBAdobe PDFThumbnail
View/Open
Show simple item record

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.